Brainstorm Cell Therapeutics (NASDAQ:BCLI) has been given a $9.00 price target by stock analysts at Maxim Group in a research note issued on Monday. The firm currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective would suggest a potential upside of 188.46% from the company’s previous close.

Separately, HC Wainwright set a $11.00 price target on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 29th.

BCLI traded down $0.03 during trading on Monday, reaching $3.12. 100 shares of the company traded hands, compared to its average volume of 52,214. Brainstorm Cell Therapeutics has a 12-month low of $2.88 and a 12-month high of $5.35. The firm has a market cap of $65.23 million, a P/E ratio of -12.00 and a beta of 2.01.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Monday, October 29th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.05). As a group, equities research analysts expect that Brainstorm Cell Therapeutics will post -0.54 EPS for the current year.

A hedge fund recently raised its stake in Brainstorm Cell Therapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 16.0% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 133,900 shares of the biotechnology company’s stock after acquiring an additional 18,500 shares during the period. Renaissance Technologies LLC owned approximately 0.65% of Brainstorm Cell Therapeutics worth $511,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.79% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Featured Story: What is a stock split?

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.